Status:

UNKNOWN

Phase I Study of CCRT as Adjuvant Treatment for Stage II/III Operable Rectal Cancer.

Lead Sponsor:

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Conditions:

Rectal Cancer

Eligibility:

All Genders

18-75 years

Phase:

PHASE1

Brief Summary

The purpose of this study is to determine the maximum tolerated dose and safety of S-1 plus radiotherapy for patients with rectal cancer

Detailed Description

This stage I study is designed to evaluate the appropriate dose of S-1 plus radiotherapy for patients with R0 resection of rectal cancer for stage II-III patients(AJCC 7th). To evaluate safety, data o...

Eligibility Criteria

Inclusion

  • R0 resection of histologically proved stage II/III rectal cancer;
  • 18-75 years old;
  • No previous radiotherapy or chemotherapy for rectal cancer;
  • Performance status of ECOG 0,1;
  • Adequate organ function defined as below:
  • i. WBC ≥ 4,000/mm\^3 ii. ANC ≥ 1,500/mm\^3 iii. Hemoglobin ≥ 10g/dL iv. Platelet ≥ 100,000/m\^3 v. Total bilirubin ≤ 1.5ULN vi. AST/ALT ≤ 1.5ULN vii. Serum creatinine ≤ 1.5ULN or creatinine clearance rate ≥ 60ml/min、Urea nitrogen ≤ 1.5ULN viii. Protein in urine dipstick test\<1+; if the test result \>1+ ,total protein in urea must \<500mg within 24 hours
  • Able to receive oral administration
  • Informed consent

Exclusion

  • Hypersensitive to S-1 or its excipients
  • Pulmonary fibrosis or interstitial pneumonitis found within 28 days prior to registration
  • Significant co-morbid medical conditions, including, but not limited to, heart failure, renal failure, hepatic failure, hemorrhagic peptic ulcer, mechanical or paralytic ileus, or poorly controlled diabetes
  • Received any investigational drug or anti-cancer agent
  • Pregnant or lactating female or pregnancy test positive
  • Severe mental disorder
  • Judged ineligible by physicians for participation in the study due to safety concern.

Key Trial Info

Start Date :

November 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2015

Estimated Enrollment :

18 Patients enrolled

Trial Details

Trial ID

NCT02277158

Start Date

November 1 2014

End Date

December 1 2015

Last Update

December 2 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Zhenzhou-Yang

Chongqing, Chongqing Municipality, China